Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Pharma Subsidiary Receives USFDA Approval for 60 mg Fluoxetine Tablets
Details : Fluoxetine hydrochloride, is an antidepressant of the SSRIs class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, etc.
Product Name : Prozac-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Pharma Gets USFDA Nod for Antidepressant Medication
Details : Fluoxetine hydrochloride (Prozac) is an SSRI antidepressant used for major depressive disorder, OCD, bulimia, and panic disorder.
Product Name : Prozac-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2010
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2010
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2023
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men
Deal Size : Inapplicable
Deal Type : Inapplicable
Improving Outcomes in Depression in Primary Care in a Low Resource Setting
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Marksans Pharma Announces UK MHRA Approval for Fluoxetine 20mg/5ml Oral Solution
Details : Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It is indicated for both acute and maintenance treatment of MDD, OCD, and bulimia nervosa; however, it is only indicated for acute treatment of ...
Product Name : Fluoxetine Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
Details : Fluoxetine is used to treat depression, panic attacks, obsessive compulsive disorder, a certain eating disorder (bulimia), and a severe form of premenstrual syndrome (premenstrual dysphoric disorder).
Product Name : Fluoxetine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2022
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2022
Lead Product(s) : Fluoxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline
Deal Size : Inapplicable
Deal Type : Inapplicable